Serioimmunological process for determining the in-vivo effective

Details Serioimmunological process for determining the in-vivo effective Serioimmunological process for determining the in-vivo effective

1983-04-14

1987-08-11

Nucker, Christine M.

Chemistry: analytical and immunological testing

Involving immune complex formed in liquid phase

436507, 436513, 436516, 436521, 436 63, G01N 33536

Patent

active

046861947

ABSTRACT:
The in-vivo effectiveness of cytostatic agents against immunological active tumors is determined by measuring immune markers and/or immune parameters in the serum before and up to 3 days after the application of the cytostatic agent. Preferably the deviation of coomplement binding capacity is used as immune parameter.

REFERENCES:
patent: 4132769 (1979-01-01), Osther
patent: 4143124 (1979-03-01), Masson et al.
patent: 4174385 (1979-11-01), Reid
Persellin, et al., Clin. Exp. Immunol., vol. 46, (1981), pp. 350-354.
Muller, et al., Eur. J. Cancer Clin. Oncol., vol. 18, No. 4, (1982), pp. 327-332.
Schwenk, et al., Klin. Padiat., vol. 190, (1978), pp. 453-459.
Stimson et al., J. Clin. Path., vol. 28, (1975), pp. 868-871.
Thomson et al., Acta. haemat., vol. 66, (1981), pp. 210-213.
Norgaard-Pedersen, et al., Immunoelectrophoretical Quantitation of Human Placental Lactogen Hormone (HPL).

Affiliated with

Also associated with

Rating

Serioimmunological process for determining the in-vivo effective does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Serioimmunological process for determining the in-vivo effective, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serioimmunological process for determining the in-vivo effective will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-402847